О клинике
Назад
О клинике О нас Хадасса в цифрах История Фототур Схема территории Новости События
Отделения
Назад
Аллергология и иммунология Гастроэнтерология Гематология Генетика Гинекология Дерматология Инфекционные заболевания Кардиология Неврология Нейрохирургия Нефрология Онкология Ортопедия Отоларингология Офтальмология Педиатрия Пластическая хирургия Психиатрия Пульмонология Радиология Радиотерапия Реабилитология Сосудистая хирургия Стоматология Торакальная хирургия Урология Хирургия Челюстно-лицевая хирургия Эндокринология Ядерная медицина Редкие заболевания Трансплантация костного мозга
Врачи
Пациентам
Назад
Отзывы и истории успеха Медицинские брошюры Пошаговое руководство Болезни от А до Я Процедуры и услуги от А до Я Прейскурант лекарств
Специалистам
Назад
Стажировки
Контакты
info@hds.org.il +9722 560-9534
О клинике
Назад
О клинике О нас Хадасса в цифрах История Фототур Схема территории Новости События
Отделения
Назад
Аллергология и иммунология Гастроэнтерология Гематология Генетика Гинекология Дерматология Инфекционные заболевания Кардиология Неврология Нейрохирургия Нефрология Онкология Ортопедия Отоларингология Офтальмология Педиатрия Пластическая хирургия Психиатрия Пульмонология Радиология Радиотерапия Реабилитология Сосудистая хирургия Стоматология Торакальная хирургия Урология Хирургия Челюстно-лицевая хирургия Эндокринология Ядерная медицина Редкие заболевания Трансплантация костного мозга
Врачи
Пациентам
Назад
Отзывы и истории успеха Медицинские брошюры Пошаговое руководство Болезни от А до Я Процедуры и услуги от А до Я Прейскурант лекарств
Специалистам
Назад
Стажировки
Контакты
info@hds.org.il +9722 560-9534

Михаль Лотем

Отделение: Онкология
Должность: Онколог
Принимает: только взрослых
Написать в WhatsApp Записаться на прием

Профессор Михаль Лотем - онколог, специалист в области лечения меланомы.

Специализация

Специалист в областях дерматологии, клинической онкологии и радиотерапии.

Основные сферы научных и клинических интересов:

  • Злокачественная меланома
  • Плоскоклеточный рак
  • Саркома Капоши
  • Лимфома кожи
  • Мониторинг родинок и других пигментированных образований
  • Синдромы с повышенной вероятностью развития рака кожи
  • Разработка и практическое применение иммунотерапии при лечении рака

Научные публикации

Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Dupilumab for cancer-associated refractory pruritus
Tumor-infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer
The future of affordable cancer immunotherapy
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions
Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy
Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma
A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells
Giant congenital melanocytic naevus with a novel CUX1-BRAF fusion mutation treated with trametinib
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphoma
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
Machine-learning of complex evolutionary signals improves classification of SNVs
Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS)
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma
Early sample tagging and pooling enables simultaneous SARS-CoV-2 detection and variant sequencing
TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR
Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions
Identification of bacteria-derived HLA-bound peptides in melanoma
COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells
Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients
SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study
Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma
Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells
Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases
Neurologic complications of immune checkpoint inhibitors
Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo
Predictors of responses to immune checkpoint blockade in advanced melanoma
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma
Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
Adoptive cell therapy: past, present and future
Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma - A case report
Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40
Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic
Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β
Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells
Human T cell crosstalk is induced by tumor membrane transfer
A new role of vemurafenib as a neoadjuvant treatment of axillary and brain melanoma metastases
Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma
Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma
Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity
The clinical effect of the inhibitor of apopotosis protein livin in melanoma
Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones
HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine
Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response
The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells
Long-term survival of uveal melanoma patients after surgery for liver metastases
Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin
Metastatic malignant melanoma involving the parotid lymph node region: a clinicopathologic report of 5 cases
Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs
Viral carcinogenesis in skin cancer
Ultraviolet radiation and cutaneous carcinogenesis
Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression
Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients
Irrigation of the bile ducts with chilled saline during percutaneous radiofrequency ablation of a hepatic ocular melanoma metastasis
Recombinant hydrophilic human gp100: uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma
PET and Lymphoscintigraphic Evaluation of Malignant Melanomas. The Hadassah Hospital Experience
Cytogenetic analysis of melanoma cell lines: subclone selection in long-term melanoma cell cultures
Mucosal melanoma of the female genital tract is a multifocal disorder
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer
Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma
CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study
Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma
Показать ещё 85 статей Скрыть статьи
Заболевания
Меланома
Рак кожи
Плоскоклеточный рак кожи
Светлоклеточная саркома
Процедуры
TIL-терапия меланомы
TCR-терапия
Метастаз-направленная терапия

Новости

Новости «Хадассы» Умная медицина в Институте Онкологии медицинского центра Хадасса
Новости «Хадассы» "Хадасса" и MyBiotics улучшат иммунотерапию меланомы
Новости «Хадассы» Онкологи просят пациентов не прекращать лечение во время пандемии
Смотреть все новости
Остались вопросы?
Напишите нам и мы свяжемся с вами в течение ближайшего времени и ответим на все интересующие вопросы